Ligand LGND 深 沪
等待开盘 05-18 09:30:00 美东时间
213.21
-5.770
-2.63%
华盛通- 最 高218.13
- 今 开216.66
- 成交量 12.79万股
- 最 低 212.70
- 昨 收 218.98
- 总市值 42.72亿
- 52周最高 247.38
- 市盈率 静 34.77
- 换手率 0.64%
- 52周最低 98.89
- 委 比 90.37%
- 总股本 2003.83万
- 历史最高 248.6071
- 量 比 0.65
- 振 幅 2.48%
- 历史最低 -19.8529
- 每 手 1
- 风险率 36.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
财报速睇 | Ligand Pharmaceuticals Incorporated 2026财年Q1营收0.52亿美元，同比增长14.1%；归母净利润亏损0.13亿美元，同比亏损缩窄68.6%
华盛资讯5月7日讯，Ligand Pharmaceuticals Incorporated公布2026财年Q1业绩，公司Q1营收0.52亿美元，同比增长14.1%，归母净利润亏损0.13亿美元，同比亏损缩窄68.6%。
05-07 19:21
Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which missed the analyst consensus estimate of $1.82 by 10.44 percent. This is a 22.56 percent increase over earnings of $1.33 per share
05-07 19:04
Orchestra BioMed Receives $15M Payment From Ligand Pharma Under Previously Disclosed Revenue Participation Right Purchase And Sale Agreement
$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra
05-06 20:07
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
04-27 23:24
Ligand to buy XOMA Royalty for $39/share
Ligand Pharmaceuticals (LGND) has agreed to acquire XOMA Royalty (XOMA) for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. The transaction has been unanimou...
04-27 19:32
Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), both biotechnology royalty aggregators, today announced that the companies have entered into a definitive
04-27 19:06
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals to acquire XOMA Royalty for $39 per share, totaling $739 million. The deal adds over 120 assets, including 7 commercial products and nearly doubles Ligand's Phase 2 and 3 pipeline. Ligand expects the transaction to be immediately accretive to EPS, raising 2026 adjusted EPS guidance to $8.50-$9.50 and adding $1.50 per share in 2027. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and stockhol...
04-27 11:00
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
